MP-A08

Research use only, not for human use.

MP-A08 is a highly selective ATP competitive inhibitor of sphingosine kinase (SPHK1) that targets both SphK1 and SphK2 (Ki: 6.9 ± 0.8 μM and 27 ± 3 μM, respectively).

MP-A08 is a highly selective ATP competitive inhibitor of sphingosine kinase (SPHK1) that targets both SphK1 and SphK2 (Ki: 6.9 ± 0.8 μM and 27 ± 3 μM, respectively).(In Vitro):MP-A08 inhibit SphK2, cause a decrease in EC barrier integrity in vitro in both cell type. MP-A08 blocks pro-proliferative signaling pathways causes mitochondrial-associated apoptosis in an SK-dependent manner. It also reduces the growth of human lung adenocarcinoma tumours in a mouse xenograft model by both inducing tumour cell apoptosis and inhibiting tumour angiogenesis (In Vivo):MP-A08 inhibits the growth of human lung tumour xenografts in mice.

MP-A08 blocks pro-proliferative signalling pathways, induces mitochondrial-associated apoptosis in a SK-dependent manner, and reduces the growth of human lung adenocarcinoma tumours in a mouse xenograft model by both inducing tumour cell apoptosis and inhibiting tumour angiogenesis. MP-A08 inhibit SphK2, cause a decrease in EC barrier integrity in vitro in both cell type.

MP-A08 suppresses the growth of human lung tumor xenografts in mice.

——

GPCR/G Protein

S1P Receptor

PHD1

——

——

219832-49-2

519.63

C27H25N3O4S2

>98% (HPLC)

In Vitro:?DMSO : ≥ 50 mg/mL (96.22 mM)

Cc1ccc(cc1)S(=O)(=O)Nc1ccccc1\C=N\c1ccccc1NS(=O)(=O)c1ccc(C)cc1

——

(-20℃)

With Ice Pack

≥ 2 years